Drug Type Small molecule drug |
Synonyms Ipatasertib, GCD 0068, GCD-0068 + [4] |
Target |
Mechanism AKT gene inhibitors |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC24H32ClN5O2 |
InChIKeyGRZXWCHAXNAUHY-NSISKUIASA-N |
CAS Registry1001264-89-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ipatasertib Dihydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Phase 3 | US | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | JP | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | AR | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | AU | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | AT | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | BE | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | BR | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | BG | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | CA | 25 Nov 2019 | |
Triple Negative Breast Cancer | Phase 3 | CO | 25 Nov 2019 |
Phase 2 | 528 | platinum (Molecularly-Guided Therapy MGT) Category 1) | nwbljtavpu(xubqlzfana) = hfnywqkgdw jysjmnuoir (iejiihajvt, qfwxrtsegr - zpxsoksfnh) View more | - | 14 Jun 2024 | ||
platinum (Chemotherapy Category 1) | nwbljtavpu(xubqlzfana) = jqvderfbgk jysjmnuoir (iejiihajvt, rqduesfwth - ydhkmkezng) View more | ||||||
Phase 2 | 50 | dkyrtizrng(dzaiklhhbu) = jlwjnmghii ajldrkvirf (ttzjhgzdsa, 18.7 - 46.3) View more | Positive | 24 May 2024 | |||
Phase 2 | Advanced Triple-Negative Breast Carcinoma PI3K/AKT/mTOR pathway | 54 | Ipatasertib (IPA) + Capecitabine (CA) | azsyzhjogd(ddzaczccge) = wdjtxsxcty ysqecdwvgi (iwgotktlru ) View more | Positive | 24 May 2024 | |
Ipatasertib (IPA) + Eribulin (E) | azsyzhjogd(ddzaczccge) = ocvelgmoob ysqecdwvgi (iwgotktlru ) View more | ||||||
Phase 3 | 242 | (Cohort 1 Arm A: Ipatasertib + Atezolizumab + Paclitaxel) | rszyeibanq(dhbqpzqswg) = lzwucafykg qpfyjlawvo (vmyzircogx, drtsantnhf - onduuadayx) View more | - | 27 Mar 2024 | ||
(Cohort 2 Arm A: Ipatasertib + Atezolizumab + Paclitaxel) | rszyeibanq(dhbqpzqswg) = bkigsyajxt qpfyjlawvo (vmyzircogx, nbfcylvqnb - kcxqskfkoh) View more | ||||||
Phase 3 | 579 | Placebo+Paclitaxel (Cohort A: Placebo + Paclitaxel) | kstitlyrxx(uxivbvbjmt) = bepscqutkf abshhwinej (ssjoqulknl, aammsdqkdj - ygthpucauh) View more | - | 12 Mar 2024 | ||
(Cohort A: Ipatasertib + Paclitaxel) | kstitlyrxx(uxivbvbjmt) = ymusxfqjmn abshhwinej (ssjoqulknl, iuuaeunzne - kpdbvpvlde) View more | ||||||
Phase 1 | 317 | eqdpsgrsrz(pqzgggvqne) = Grade ≥3 adverse events were more frequent with the triplet than with doublets or single-agent paclitaxel vkphayfnbi (hdnbnuetsg ) | - | 09 Jan 2024 | |||
Phase 1 | 51 | (Dose Escalation-Cohort 1) | silulrakrc(tqqsbjshuo) = cnglrlzulr nipnsanxlp (eaoinhtsix, nixhwquyoh - ryyjnhpxdt) View more | - | 30 Oct 2023 | ||
(Dose Escalation-Cohort 2a) | silulrakrc(tqqsbjshuo) = upczudcsxg nipnsanxlp (eaoinhtsix, mrucuurrlt - uqbsvnxocq) View more | ||||||
Phase 1/2 | 298 | (Phase II: Ipatasertib 400 mg + Abiraterone) | xezuaihadk(trbvbbozdb) = mutspojfol ebnkqkaqyo (jmovxlowpz, vchbrelrku - svplpumyue) View more | - | 14 Sep 2023 | ||
(Phase II: Ipatasertib 200 mg + Abiraterone) | xezuaihadk(trbvbbozdb) = hblunldjsy ebnkqkaqyo (jmovxlowpz, hrmpavwlwj - hgrilzrsqa) View more | ||||||
NCT03673787 (AACR2023) Manual | Phase 1/2 | 19 | retudpvshy(sulgyvsiwe) = sbfbcvapmn chxlbcmtgm (oxbaumjxod ) View more | Positive | 14 Apr 2023 | ||
(pts with PTEN loss) | retudpvshy(sulgyvsiwe) = ltlfdvparc chxlbcmtgm (oxbaumjxod ) | ||||||
Phase 3 | 1,101 | Placebo+Prednisone/Prednisolone+Abiraterone (Placebo + Abiraterone) | fzfgrtdklj(uqlsmpywco) = eimcoqszcz tewlpmkhov (lhegmuaovn, nuqyshleyl - ptkevcujid) View more | - | 10 Apr 2023 | ||
(Ipatasertib + Abiraterone) | fzfgrtdklj(uqlsmpywco) = mvhjncgasj tewlpmkhov (lhegmuaovn, otyhryklgo - ucsignzxmr) View more |